TISAGENLECLEUCEL

UNII:	Q6C9WHR03O
Formula:
Preferred Substance Name:	TISAGENLECLEUCEL

1823078-37-0
CAR.CD19-REDIRECTED T CELLS
CART19
CART-19
CTL019
CTL-019
GENE MODIFICATION OF T CELLS IS MEDIATED BY STABLE INSERTION VIA TRANSDUCTION WITH A SELF-INACTIVATING, REPLICATION-DEFICIENT LENTIVIRAL (LV) VECTOR CONTAINING THE CTL019 TRANSGENE UNDER THE CONTROL OF THE EF-1 ALPHA PROMOTER. THE DRUG PRODUCT IS A MIXTURE OF TRANSGENE POSITIVE AND NEGATIVE T CELLS THAT ARE DELIVERED TO THE PATIENT ON THE BASIS OF PERCENT TRANSGENE POSITIVE T CELLS.
KYMRIAH
TISAGENLECLEUCEL [INN]
TISAGENLECLEUCEL [USAN]
TISAGENLECLEUCEL [WHO-DD]
TISAGENLECLEUCEL-T

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

TISAGENLECLEUCEL

Synonyms and Mappings

Resources